drugset / Trial / NCT01503229
Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
NaSingle-groupOpen-labelTreatment
Summary
This phase II trial studies how well abiraterone acetate works in treating patients with hormone-resistant prostate cancer that has spread from the primary site (place where it started) to other places in the body (metastatic). Abiraterone acetate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Timeline
- Start
- 2012-12
- Primary completion
- 2020-03-12
- Completion
- 2020-03-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abiraterone acetate | Small molecule | — | Oral |
| Background | Prednisone | Other / unclassified | — | Oral |